Institutional
GSK plc (GSK, GLAXF)
CIK 0001131399
$599.2M
Reported AUM
13
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · GSK plc (GSK, GLAXF) · Q1 2026
AI · grounded in 13F
GSK plc closed its position in Senseonics Hldgs Inc SENS, reducing its holdings by $59,925. The fund also exited its position in Harvard Bioscience Inc HBIOUSD for a total of $7,458. These two divestments represent the only changes to a portfolio consisting of 13 positions with a total AUM of $599,153,380.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRSP | CRISPR THERAPEUTICS AG | $48.03 | -0.85% | -13.64% | -61.23% | $153.2M | 25.57% | — | HELD |
| 2 | WVE | WAVE LIFE SCIENCES LTD | $5.53 | -3.91% | -35.52% | -12.09% | $132.3M | 22.08% | — | HELD |
| 3 | BNTX | BIONTECH SE | $90.82 | -2.19% | -13.33% | -71.36% | $79.1M | 13.20% | — | HELD |
| 4 | VIR | VIR BIOTECHNOLOGY INC | $8.59 | -3.48% | 70.28% | -83.38% | $76.6M | 12.79% | — | HELD |
| 5 | IDYA | IDEAYA BIOSCIENCES INC | $35.55 | -2.34% | 49.98% | 54.89% | $44.4M | 7.41% | — | HELD |
| 6 | LYEL | LYELL IMMUNOPHARMA INC | $13.06 | -4.85% | 24.50% | -95.66% | $30.3M | 5.06% | — | HELD |
| 7 | CYTK | CYTOKINETICS INC | $77.74 | -3.33% | 112.78% | 136.79% | $22.4M | 3.74% | — | HELD |
| 8 | SPRO | SPERO THERAPEUTICS INC | $1.18 | -1.67% | -48.70% | -93.87% | $21.5M | 3.59% | — | HELD |
| 9 | FULC | FULCRUM THERAPEUTICS INC | $3.57 | -4.17% | -45.53% | -87.47% | $13.7M | 2.29% | — | HELD |
| 10 | CVRX | CVRX INC | $5.12 | -4.83% | -28.84% | -71.77% | $9.5M | 1.59% | — | HELD |
| 11 | BCYC | BICYCLE THERAPEUTICS PLC | $3.84 | -4.25% | -49.81% | -88.77% | $7.1M | 1.18% | — | HELD |
| 12 | NKTX | NKARTA INC | $2.08 | -3.26% | -2.83% | -93.63% | $6.6M | 1.11% | — | HELD |
| 13 | RGNX | REGENXBIO INC | $9.70 | -4.15% | 23.57% | -68.67% | $2.3M | 0.38% | — | HELD |
Source: SEC EDGAR · accession 0001999371-26-010742. 13F discloses long positions only — shorts, foreign equities, and options are excluded.